Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A drug has a bioavailability of 80% and a volume of distribution of 10 L. Calculate the loading dose required to achieve a plasma concentration of 0.6 mg/L.

7.5 mg. ### Explanation **1. Understanding the Correct Answer (C: 7.5 mg)** The **Loading Dose (LD)** is the initial dose given to rapidly achieve the desired steady-state plasma concentration ($C_p$). The fundamental formula for calculating the loading dose is: $$LD = \frac{V_d \times C_p}{F}$$ * **$V_d$ (Volume of Distribution):** 10 L * **$C_p$ (Target Plasma Concentration):** 0.6 mg/L * **$F$ (Bioavailability):** 80% or 0.8 (This must be accounted for if the drug is not given intravenously). **Calculation:** $$LD = \frac{10 \text{ L} \times 0.6 \text{ mg/L}}{0.8}$$ $$LD = \frac{6 \text{ mg}}{0.8} = 7.5 \text{ mg}$$ **2. Why Incorrect Options are Wrong** * **Option B (0.48 mg) & D (48 mg):** These result from mathematical errors or misplacing decimal points. 48 mg is the result of multiplying all numbers ($10 \times 0.6 \times 8$) without considering the division by bioavailability. * **Option A (0.75 mg):** This is a decimal error. While the digits are correct, the magnitude is off by a factor of 10. **3. NEET-PG Clinical Pearls & High-Yield Facts** * **Loading Dose vs. Maintenance Dose:** Remember that **Loading Dose** depends primarily on the **Volume of Distribution ($V_d$)**, whereas the **Maintenance Dose** depends on **Clearance ($CL$)**. * **Bioavailability ($F$):** For IV administration, $F = 1$. If the question does not specify the route but provides $F$, always include it in the denominator. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration. A loading dose bypasses this delay, which is critical in emergencies (e.g., Lidocaine for arrhythmias or Digoxin for heart failure). * **Vd Concept:** A high $V_d$ (> 42L) suggests the drug is sequestered in tissues (lipophilic), while a low $V_d$ suggests the drug remains in the plasma (large molecules or highly protein-bound).

Q: Which of the following receptors acts the slowest?

Mineralocorticoid receptor. **Explanation:** The speed of a receptor's response is determined by its **mechanism of signal transduction**. Receptors are categorized into four types based on their latency (time to effect): 1. **Mineralocorticoid Receptor (Correct):** This is a **Type 4 (Nuclear/Intracellular) receptor**. These receptors act as ligand-regulated transcription factors. When a hormone (like Aldosterone) binds, the receptor-ligand complex translocates to the nucleus to alter gene expression and protein synthesis. Because this involves transcription and translation, the response takes **hours to days**, making it the slowest class of receptors. **Why the other options are incorrect:** * **Beta 1 and M2 Receptors (Options A & B):** These are **Type 2 (G-Protein Coupled Receptors - GPCRs)**. They work via second messengers (cAMP, IP3/DAG). Their response time is in **seconds**, which is significantly faster than nuclear receptors but slower than ion channels. * **Tyrosine Kinase Receptor (Option C):** This is a **Type 3 (Enzyme-linked) receptor** (e.g., Insulin receptor). These involve a phosphorylation cascade and typically act within **minutes to hours**. **High-Yield NEET-PG Pearls:** * **Fastest Receptors:** Type 1 (Inotropic/Ligand-gated ion channels) like Nicotinic (Nm/Nn) or GABA-A receptors. They act in **milliseconds**. * **Slowest Receptors:** Type 4 (Nuclear). Examples include Steroids (Glucocorticoids, Mineralocorticoids), Thyroid hormones (T3/T4), Vitamin D, and Retinoic acid. * **Memory Aid:** The further the signal has to travel (from membrane → cytoplasm → nucleus → DNA → Protein), the slower the response.

Q: Which route of administration provides 100% bioavailability?

Intravenous. **Explanation:** **1. Why Intravenous (IV) is Correct:** Bioavailability ($F$) is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is administered **Intravenously**, it bypasses all absorption barriers and the "first-pass metabolism" in the liver. The entire dose enters the bloodstream immediately; therefore, by definition, the bioavailability of the IV route is **100% ($F = 1.0$)**. This makes it the gold standard for emergencies where a rapid onset of action is required. **2. Why Other Options are Incorrect:** * **Oral:** This route typically has the lowest and most variable bioavailability due to incomplete absorption from the GI tract and significant **First-Pass Metabolism** (pre-systemic elimination) in the gut wall and liver. * **Rectal:** While it partially bypasses the liver (the lower rectum drains into the systemic circulation via inferior vena cava), absorption is often erratic and incomplete, leading to <100% bioavailability. * **Subcutaneous:** Drugs must diffuse through connective tissue and capillaries to reach the circulation. While usually higher than oral, it is still <100% due to local degradation or slow absorption. **3. NEET-PG High-Yield Pearls:** * **Definition:** Bioavailability is calculated by comparing the **Area Under the Curve (AUC)** of a specific route to the AUC of the IV route: $F = \frac{AUC_{oral}}{AUC_{IV}} \times 100$. * **First-Pass Effect:** Major sites are the **Liver** (most common) and **Gut** (e.g., Tyramine, Midazolam). * **Exceptions:** Some oral drugs like **Warfarin, Diazepam, and Digoxin** have nearly 100% bioavailability despite being given orally. * **Clinical Note:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Lignocaine) cannot be given orally and require sublingual or IV routes.

Q: A 70 kg man was given a drug in a dose of 100 mg/kg body weight. Its half-life is 10 hours, and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Elimination rate constant (k) is 0.0693 hr -1. ### Explanation **1. Why Option C is Correct** The question provides the **half-life ($t_{1/2}$)** of the drug as 10 hours. In pharmacokinetics, the elimination rate constant ($k$) represents the fraction of a drug removed per unit of time [1]. The relationship between half-life and the elimination rate constant is defined by the formula: $k = \frac{0.693}{t_{1/2}}$ Plugging in the values: $k = \frac{0.693}{10 \text{ hours}} = 0.0693 \text{ hr}^{-1}$ This indicates that approximately 6.93% of the drug is eliminated every hour. **2. Why Other Options are Incorrect** * **Option D:** This is a decimal point error ($6.93$ vs $0.0693$). Such distractors are common in NEET-PG to test calculation accuracy. * **Options A & B (Clearance):** To calculate Clearance ($CL$), we first need the Volume of Distribution ($V_d$). * Total Dose = $100 \text{ mg/kg} \times 70 \text{ kg} = 7000 \text{ mg}$. * $V_d = \frac{\text{Dose}}{\text{Plasma Concentration}} = \frac{7000 \text{ mg}}{1.9 \text{ mg/ml}} \approx 3684 \text{ ml}$ or $3.68 \text{ L}$. * $CL = k \times V_d = 0.0693 \times 3.68 \approx 0.25 \text{ L/hr}$. Neither 0.02 nor 0.2 L/hr is the precise value, making these options mathematically incorrect. **3. Clinical Pearls & High-Yield Facts** * **First-Order Kinetics:** Most drugs follow first-order kinetics, where a **constant fraction** of the drug is eliminated per unit time ($k$ is constant) [1]. * **Zero-Order Kinetics:** A **constant amount** of drug is eliminated (e.g., Phenytoin, Alcohol, Salicylates at high doses) [1]. Here, $t_{1/2}$ is not constant. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body. * **Formula Recap:** $CL = V_d \times k$ and $t_{1/2} = \frac{0.693 \times V_d}{CL}$.

Q: A loading dose of 25 mg was administered to achieve a plasma concentration of 0.5 mg/L. If the volume of distribution is 40 L, what is the bioavailability?

80%. ### Explanation **1. Understanding the Correct Answer (C: 80%)** The core concept here is the relationship between **Loading Dose (LD)**, **Volume of Distribution (Vd)**, **Target Plasma Concentration (Cp)**, and **Bioavailability (F)**. The standard formula for Loading Dose is: $$LD = \frac{Cp \times Vd}{F}$$ To find the Bioavailability (F), we rearrange the formula: $$F = \frac{Cp \times Vd}{LD}$$ **Calculation:** * Target Concentration (Cp) = 0.5 mg/L * Volume of Distribution (Vd) = 40 L * Administered Dose (LD) = 25 mg $$F = \frac{0.5 \text{ mg/L} \times 40 \text{ L}}{25 \text{ mg}}$$ $$F = \frac{20 \text{ mg}}{25 \text{ mg}} = 0.8$$ To express this as a percentage: $0.8 \times 100 = \mathbf{80\%}$. **2. Why Other Options are Incorrect** * **A (40%), B (50%), and D (70%):** These values do not satisfy the pharmacokinetic equation. If the bioavailability were 40% or 50%, the achieved plasma concentration would be significantly lower than 0.5 mg/L for the same dose, as more of the drug would be "lost" before reaching systemic circulation. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **Loading Dose:** It is used to achieve the **Steady State Concentration (Css)** rapidly. It depends primarily on the **Volume of Distribution** and is independent of the drug's half-life ($t_{1/2}$). * **Maintenance Dose:** This is used to maintain the Css and depends primarily on the **Clearance (CL)** of the drug. * **Bioavailability (F):** For intravenous (IV) administration, $F = 1$ (or 100%). For any other route (oral, IM, etc.), $F$ is usually $< 1$ due to incomplete absorption or first-pass metabolism. * **Vd Concept:** A drug with a high Vd (e.g., Digoxin, Chloroquine) is sequestered in tissues and requires a higher loading dose to achieve target plasma levels.

Q: Which of the following receptors is coupled to a heterotrimeric G protein?

GABA-B receptor. **Explanation:** The core concept tested here is the classification of receptors into **Ionotropic** (ligand-gated ion channels) and **Metabotropic** (G-protein coupled receptors or GPCRs). **Why GABA-B is correct:** The **GABA-B receptor** is a metabotropic receptor coupled to a **heterotrimeric G-protein** (specifically $G_i/G_o$). Activation of GABA-B leads to the inhibition of adenylyl cyclase, opening of potassium ($K^+$) channels (causing hyperpolarization), and closing of calcium ($Ca^{2+}$) channels. This mediates slow, prolonged inhibitory postsynaptic potentials. **Why the other options are incorrect:** * **Glycine receptor (Option A):** This is an **ionotropic** receptor. It is a pentameric chloride ($Cl^-$) channel that mediates fast inhibition in the spinal cord and brainstem. * **Nicotinic ACh receptor (Option C):** The Nm receptor at the neuromuscular junction is a classic **ionotropic** receptor. It is a ligand-gated cation channel ($Na^+/K^+$) that mediates rapid skeletal muscle contraction. * **5-HT3 receptor (Option D):** This is the **only ionotropic serotonin receptor**. All other serotonin receptors (5-HT1, 2, 4–7) are GPCRs. 5-HT3 is a non-selective cation channel involved in the emetic reflex. **High-Yield Clinical Pearls for NEET-PG:** * **GABA-A vs. GABA-B:** Remember "A" for **A**qua/Ion (Ionotropic - $Cl^-$ channel) and "B" for **B**oth/GPCR (Metabotropic). * **Baclofen** is a specific GABA-B agonist used clinically as a centrally acting muscle relaxant for spasticity. * **Fast vs. Slow:** Ionotropic receptors (A, C, D) act in milliseconds, while GPCRs (B) take seconds to minutes. * **Common Ionotropic Receptors (Mnemonic: "GANG"):** **G**ABA-A, **A**MPA/NMDA/Kainate, **N**icotinic, **G**lycine, and 5-HT3.

Q: Which of the following drugs is deposited in the muscles?

Digoxin. **Explanation:** The correct answer is **Digoxin**. This question tests the concept of **Volume of Distribution ($V_d$)** and tissue-specific binding [1]. **1. Why Digoxin is Correct:** Digoxin has an exceptionally large volume of distribution (~5–7 L/kg) because it is extensively sequestered in peripheral tissues, specifically **skeletal muscle** and the heart [1]. It binds to the Na+/K+-ATPase pump in these tissues [1],[3]. Because skeletal muscle represents a large percentage of total body mass, it serves as the primary reservoir for Digoxin [1]. * **Clinical Correlation:** In obese patients, Digoxin dosage should be calculated based on **Lean Body Weight (LBW)** rather than total body weight, as Digoxin does not distribute into adipose tissue. **2. Why the Other Options are Incorrect:** * **Verapamil:** While it has a large $V_d$, it does not show the characteristic high-affinity sequestration in skeletal muscle that Digoxin does. It is primarily metabolized by the liver. * **Adenosine:** It has an extremely short half-life (<10 seconds) because it is rapidly taken up by erythrocytes and endothelial cells and metabolized. It does not have time to deposit in muscles. * **Phenytoin:** It is highly protein-bound (mainly to albumin) and follows zero-order kinetics at high therapeutic concentrations [2]. It does not sequester in skeletal muscle. **High-Yield NEET-PG Pearls:** * **Tissue Reservoirs:** * **Muscle:** Digoxin [1] * **Adipose Tissue:** Thiopental, Amiodarone * **Bone/Teeth:** Tetracyclines, Fluoride * **Retina:** Chloroquine (binds to melanin) * **Liver:** Chloroquine, Emetine * **Digoxin Monitoring:** Since Digoxin is sequestered in muscles, plasma levels do not reflect tissue levels immediately after administration. Blood for Therapeutic Drug Monitoring (TDM) should be drawn at least **6–8 hours** after the last dose to allow for distribution [4].

Q: An agonist has which of the following characteristics?

Affinity with intrinsic activity of 0. **Explanation** In pharmacology and neuroanatomy, the interaction between a ligand and a receptor is defined by two key properties: **Affinity** (the ability of a drug to bind to a receptor) and **Intrinsic Activity/Efficacy** (the ability of a drug to activate the receptor and produce a biological response). **Why Option A is Correct:** An **Antagonist** (often referred to as a "blocker") possesses **affinity** for the receptor, allowing it to occupy the binding site. However, it has an **intrinsic activity of 0**. This means it does not trigger any conformational change to activate the receptor; instead, it simply prevents an agonist from binding, thereby inhibiting its effect. **Analysis of Incorrect Options:** * **Option B (Intrinsic Activity of 1):** This describes a **Full Agonist**. These drugs bind to the receptor and produce the maximum possible biological response. * **Option C (Intrinsic Activity of -1):** This describes an **Inverse Agonist**. These drugs bind to the same receptor as an agonist but produce a response that is pharmacologically opposite to that of the agonist (only possible in receptors with constitutive activity). * **Partial Agonists** (not listed) have an intrinsic activity between 0 and 1. **NEET-PG High-Yield Pearls:** 1. **Competitive Antagonism:** Shifts the Dose-Response Curve (DRC) to the **right**, increasing the $ED_{50}$ but maintaining the same $V_{max}$ (can be overcome by increasing agonist concentration). 2. **Non-competitive Antagonism:** Flattens the DRC, decreasing the $V_{max}$ (cannot be overcome by more agonist). 3. **Key Example:** Naloxone is a competitive antagonist at opioid receptors, used to reverse respiratory depression in overdose cases.

Q: A 70 kg man was given a drug at a dose of 100 mg/kg body weight. The drug's half-life (t1/2) is 10 hours and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

The elimination rate constant (k) is 0.0693 hr^-1.. ### Explanation This question tests your understanding of basic pharmacokinetics, specifically the relationship between half-life ($t_{1/2}$) and the elimination rate constant ($k$). **1. Why Option C is Correct:** The elimination rate constant ($k$) represents the fraction of a drug removed per unit of time. It is inversely proportional to the half-life. The standard formula for a first-order kinetic process is: $k = rac{0.693}{t_{1/2}}$ Given $t_{1/2} = 10$ hours: $k = rac{0.693}{10} = 0.0693 \text{ hr}^{-1}$ This indicates that approximately 6.93% of the drug is eliminated every hour. **2. Why Other Options are Incorrect:** * **Option D:** This is a decimal point error ($6.93$ vs $0.0693$). * **Options A & B (Clearance):** To calculate Clearance ($CL$), we first need the Volume of Distribution ($V_d$). * $V_d = \frac{\text{Total Dose}}{\text{Initial Plasma Concentration}}$ * Total Dose = $100 \text{ mg/kg} \times 70 \text{ kg} = 7000 \text{ mg}$. * $V_d = \frac{7000 \text{ mg}}{1.9 \text{ mg/ml}} \approx 3684 \text{ ml}$ or $3.68 \text{ L}$. * $CL = k \times V_d = 0.0693 \times 3.68 \approx 0.255 \text{ L/hr}$ [1]. Neither 0.02 nor 20 L/hr matches the calculated clearance. **3. NEET-PG High-Yield Pearls:** * **First-Order Kinetics:** A constant **fraction** of drug is eliminated per unit time (most drugs). $t_{1/2}$ is constant. * **Zero-Order Kinetics:** A constant **amount** of drug is eliminated per unit time (e.g., Ethanol, Phenytoin, Aspirin at high doses). $t_{1/2}$ is variable. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body. * **Loading Dose:** Depends primarily on $V_d$ ($LD = V_d \times C_p$) [1]. * **Maintenance Dose:** Depends primarily on $CL$ ($MD = CL \times C_{ss}$).

Question 1

A drug has a bioavailability of 80% and a volume of distribution of 10 L. Calculate the loading dose required to achieve a plasma concentration of 0.6 mg/L.

Accepted Answer

7.5 mg

Answer

0.75 mg

Answer

0.48 mg

Answer

48 mg

Question 2

Which of the following receptors acts the slowest?

Accepted Answer

Mineralocorticoid receptor

Answer

Beta 1 receptor

Answer

M2 receptor

Answer

Tyrosine kinase receptor

Question 3

Which route of administration provides 100% bioavailability?

Accepted Answer

Intravenous

Answer

Oral

Answer

Rectal

Answer

Subcutaneous

Question 4

A 70 kg man was given a drug in a dose of 100 mg/kg body weight. Its half-life is 10 hours, and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Accepted Answer

Elimination rate constant (k) is 0.0693 hr
-1

Answer

Clearance is 0.02 litre/hr

Answer

Clearance is 0.2 litre/hr

Answer

Elimination rate constant (k) is 6.93 hr
-1

Question 5

A loading dose of 25 mg was administered to achieve a plasma concentration of 0.5 mg/L. If the volume of distribution is 40 L, what is the bioavailability?

Accepted Answer

80%

Answer

40%

Answer

50%

Answer

70%

Question 6

Which of the following receptors is coupled to a heterotrimeric G protein?

Accepted Answer

GABA-B receptor

Answer

Glycine receptor

Answer

Nicotinic acetylcholine receptor at myoneural junction

Answer

5-HT3 receptor

Question 7

Which of the following drugs is deposited in the muscles?

Accepted Answer

Digoxin

Answer

Verapamil

Answer

Adenosine

Answer

Phenytoin

Question 8

An agonist has which of the following characteristics?

Accepted Answer

Affinity with intrinsic activity of 0

Answer

Affinity with intrinsic activity of 1

Answer

Affinity with intrinsic activity of -1

Answer

None of the above

Question 9

Which drug transport process requires energy?

Accepted Answer

Active transport

Answer

Passive diffusion

Answer

Convective current

Answer

Pinocytosis

Question 10

A 70 kg man was given a drug at a dose of 100 mg/kg body weight. The drug's half-life (t1/2) is 10 hours and the initial plasma concentration is 1.9 mg/ml. Which of the following statements is true?

Accepted Answer

The elimination rate constant (k) is 0.0693 hr^-1.

Answer

The clearance (CL) is 0.02 litre/hr.

Answer

The clearance (CL) is 20 litre/hr.

Answer

The elimination rate constant (k) is 6.93 hr^-1.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?